natgillin/translations-raw huggingface dataset:
A method of forming a security document (1), comprising the steps of: 
Postupak pravljenja sigurnosnog dokumenta (1), naznačen time što se sastoji u koracima:
whereby the anchoring movement of the bayonet-type attachment system also causes the mandrel-like terminals to be engaged in the opposing fork-shaped terminals. 
HR P20110099 T1 time, da se pomicanjem bajunetnog sustava s bajunetom radi pričvršćivanja sklopa također terminali u obliku letve prikopčavaju na nasuprotne terminale račvastog oblika.
rotating the container inside the vacuum chamber so as to tumble the organic material in the container; 
rotiranja posude (38) unutar vakuumske komore (22) oko horizontalne osi;
The liquefied gas treatment system according to claim 8, wherein the BOG, which is compressed by the compressor and is transferred to the heat exchanger, is compressed while passing through all or part of the plurality of compression cylinders included in the compressor. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 7, naznačen time što se BOG, koji se komprimira kompresorom (150;13), te prebaci u izmjenjivač topline (21), komprimira prilikom prolaska kroz sve ili dio od više kompresijskih cilindara (14) koje sadrži kompresor.
Testosterone or an analogue thereof having the same kind of activity, for use in the treatment of female sexual dysfunction, in combination with tadalafil, wherein said testosterone or an analogue thereof and tadalafil are released at the same time and wherein said testosterone or an analogue thereof is provided as a sublingual, buco-mucoasal, or intranasal formulation such that a peak serum level of testosterone is obtained 1-20 minutes after administration such that the peak effects of testosterone or an analogue thereof and tadalafil overlap. 
Testosteron ili njegov analog koji ima istu vrstu aktivnosti, za uporabu u liječenju ženske seksualne disfunkcije, u kombinaciji sa tadalafilom, naznačen time što se navedeni testosteron ili njegov analog 1 tadalafil oslobađaju u isto vrijeme i gdje su navedeni testosteron ili njegov analog pruženi u vidu sublingvalne, buko-mukozne ili intranazalne formulacije, tako da se pik nivoa testosterona u serumu postiže 1-20 minuta nakon primjene, pa se pikovi efekata testosterona ili njegovog analoga i tadalafila preklapaju.
A process for preparing crystalline [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid (Compound A), comprising contacting Compound A, or a salt thereof, with acetic acid for a time sufficient to provide a crystalline Compound A wherein at least about 95% of the crystalline Compound A is Form A. 
Kristalna [(4-hidroksi-1-metil-7-fenoksi-izohinolin-3-karbonil)-amino]-octena kiselina (Spoj A Oblika A) naznačena da ima difraktogram X-zraka na prahu koji sadrži slijedeće maksimalne vrijednosti: 8.5, 12.8, 16.2, 21.6, 22.9, i 27.4 °2θ ± 0.2 °2θ, kada se mjeri upotrebom Cu Ka zračenja.
In a first aspect, an immunobinder is provided comprising one of the following solubility enhancing motifs in the heavy chain amino acid positions 12, 103 and 144 (AHo numbering): 
HR P20171250 T1 PATENTNI ZAHTJEVI no Imunovezno sredstvo, naznačeno time, da obuhvaća sljedeće motive pojačanja topivosti na aminokiselinskim pozicijama 12, 103 i 144 jakog lanca (AHo-numeriranje):
if the single rearranged human immunoglobulin light chain variable region is derived from a rearranged Vk3-20 gene sequence, the Vk3-20 gene sequence comprises a replacement of at least one non-histidine codon with a histidine codon designed to express a histidine 
jedna preuređena genska sekvenca varijabilne regije humanog imunoglobulinskog lakog lanca sadrži Vk3-20/Jk koja se sastoji od zamjene najmanje jednog nehistidinskog kodona histidinskim kodonom dizajniranim da izražava histidin
Method for preventing, slowing, delaying or treating diseases or conditions attributed to an abnormal accumulation of ectopic fat in a patient in need thereof characterized in that an SGLT2 inhibitor, a DPP IV inhibitor and a third antidiabetic agent according to claim 1 are administered to the patient. 
za prevenciju, usporavanje, odgađanje ili liječenje bolesti ili stanja koja se pripisuju abnormalnoj akumulaciji ektopične masnoće; ili održavanje i/ili poboljšanje osjetljivosti na inzulin i/ili za liječenje ili prevenciju hiperinzulinemije i/ili otpornosti na inzulin;
said bending station (Ph3) has a bending mechanism (12) that includes a pair of roller bending tools (13,14) and a pair of advancement rollers (37,38). 
Navedena stanica za savijanje (Ph3), ima mehanizam za savijanje (12) koji sadrži par valjaka kao alat za savijanje (13, 14), i par valjaka za pomjeranje (37, 38).
is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, cyano, C1-4alkyl, C1-4alkyloxy, C1-4alkylsulfonyl, perfluoroC1-4alkyl, perfluoroC1-4alkyloxy, diC1-4alkylamino, hydroxyl, and phenyl optionally substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, C1-4alkyl and perfluoroC1-4alkyl; thienyl; thienyl substituted with 1 or 2 substituents each independently selected from the group consisting of halo and C1-4alkyl; naphthyl; pyridinyl; pyrrolyl; benzothiazolyl; indolyl; quinolinyl; C3-8cycloalkyl; or C5-7cycloalkenyl; is hydrogen, C1-4alkyl, C1-4alkyloxy or halo; 
R* je fenil; fenil supstituiran sa 1, 2 ili 3 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo, cijano, Cisalkil, Ciaalkiloksi, Ciaalkilsulfonil, perfluoroC,.alkil, perfluoroC,alkiloksi, diC,valkilamino, hidroksil, 1 fenil proizvoljno supstituiran sa 1, 2 ili 3 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo, Ciaalkil 1 perfluoroC,aalkil; tienil; tienil supstituiran sa 1 ili 2 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo i C,aalkil; naftil; piridinil; pirolil; benzotiazolil; indolil; kinolinil; C3. sCikloalkil; ili Cs.gcikloalkenil; R? je vodik, Cisalkil, C,aalkiloksi ili halo;
A white solid was obtained. 
Dobivena je bijela krutina.
ID. NO:73 and a light chain variable region encoded by SEQ. 
ID. NO:73 1 varijabilno područje lakog lanca kojeg kodira SEQ.
a cytokine, antibody or antibody fragment, which cytokine, antibody or antibody fragment specifically binds to an antigen or receptor on the exterior of said cell, conjugated or fused to 
citokin, antitijelo ili fragment antitijela, koji se citokin, antitijelo ili fragment antitijela specifično vežu na neki antigen ili receptor vanjskog dijela spomenute stanice, konjugiran ili fuzioniran sa
The present invention relates to the method of manufacturing of 7-ethyl-10-hydroxycamptothecin of formula I 
Ovaj izum odnosi se na postupak dobivanja 7-etil-10-hidroksikamptotecina formule I
The speed of the rotor was set at 450 rev/min in the first 15 minutes of the pelletization and later kept at 600 rev/min. 
Brzina rotora održavana je na 450 okr/min tijekom prvih 15 minuta granuliranja i nakon toga na 600 okr/min. HR P20070322 T3
The compound according to claim 1, wherein X is N, Ar is phenyl or pyridyl, which is unsubstituted or mono- or disubstituted by Hal, LA or O(LA), 
je H ili LA, Ar je fenil ili piridil, koji je nesupstituiran ili mono- ili disupstituiran s Hal, LA ili O(LA), ili u Podformuli 12 X je N, Y je CNH2, E je -CH(R3)-NH-CO- ili -CO-NH-CH(R3)-,
Use of a compound or a pharmaceutically acceptable salt or solvate thereof as claimed in any of claims 1 to 3 in the manufacture of a medicament for the treatment of inflammatory diseases, disorders and conditions characterized by or associated with excessive unregulated production of cytokines or inflammatory mediators. 
Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3 u proizvodnji medikamenta za liječenje upalnih bolesti, poremećaja i stanja, naznačena time što je ili jo povezana s prekomjernom nereguliranom proizvodnjom citokina ili posrednika upale.
A pharmaceutical composition comprising as active ingredient at least one compound of formula (I) as defined in any one of the claims 1 to 11 or an optical isomer, pharmaceuctically acceptable salt, hydrate, solvate or polymorph thereof, together with one or more pharmaceutically acceptable excipients. 
Farmaceutski spoj koji kao aktivne tvari sadrži barem jednu of formula (I) kako su definirane bilo kojem od zahtjeva 1 do 10 ili spoj (6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (3,4- dihidro- 1H- izokvinolin- 2- il)- metanon ili njihove optičke izomere, farmaceutski prihvatljive soli, hidrate, otopine ili polimorfe, zajedno sa jednim ili više farmaceutski prihvatljivih ekscipijenata.
The method according to claim 1, further comprising a further active agent, provided that the further active agent is not an interferon. 
CCI-779, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što dodatno sadrži dodatno aktivno sredstvo, uz uvjet da dodatno aktivno sredstvo nije interferon.
The system of claim 1, wherein the propelling means comprises a rail system, a cable system, a manually propelled system, a robotic system, a system guided from a distance, a boat with an engine, a floating device with an engine, or a combination thereof. 
Sustav prema bilo kojem prethodnom zahtjevu, naznačen time što pogonska sredstva (4) obuhvaćaju tračnički sustav, kabelski sustav, samohodni sustav, robotski sustav, sustav vođen iz daljine, brod s motorom, plutajući uređaj s motorom ili njihovu kombinaciju.
compound of formula (XXI) is first reacted with the reagent (M-A) and then the reagent (M-reag) is added; or 
Ili spoj formule (XXI) bude pomiješan najprije sa reagensom (M-A) i tada bude dodan reagens (M-reag.);
to 50 wt.%, particularly 1 to 50 wt.%, preferably 10 to 40 wt.% and more preferably 15 to 30 wt.% of said release modifying material; 
(c) 0 do 50 masenih %, posebno 1 do 50 masenih %, poželjno 10 do 40 masenih % i najpoželjnije 15 do 30 masenih % navedenog materijala koji modificira oslobađanje;
Another object of the present invention is the use of the compounds according to the invention for the treatment and/or prophylaxis of diseases based on hormone-dependent hyperproliferative processes, preferably of gynaecological diseases, in particular of fibroids of the uterus, endometriosis or hormone-dependent breast cancers. 
Uporaba spoja prema zahtjevu 5 naznačena time da se koristi za pripravljanje lijeka za liječenje i/ili profilaksu fibroida maternice, endometrioze, teškog menstrualnog krvarenja, meningeoma, hormonski-ovisnih karcinoma dojke 1 simptoma povezanih s menopauzom ili za kontrolu plodnosti i hitnu kontracepciju.
The composition of claim 10 comprising about 2 mg to about 50 mg of buprenorphine. 
Pripravak sukladno patentnom zahtjevu 1 sadrži 2 mg do 50 mg buprenorfina.
A salt according to any one of the preceding claims, wherein the amine is selected from the group consisting of L-arginine, deanol, diethanolamine, diethylethanolamine, ethanolamine, meglumine, 2-morpholine ethanol, 1-(2-hydroxyethyl)-pyrrolidine, triethanolamine and tromethamine; preferably from the group consisting of L-arginine, diethanolamine, meglumine, triethanolamine and tromethamine. 
Sol prema jednom od prethodnih zahtjeva, naznačena time, što je amin odabran iz grupe koju čine L-arginin, deanol, dietanolamin, dietiletanolamin, etanolamin, meglumin, 2-morfolin etanol, 1-(2-hidroksietil)-pirolidin, trietanolamin i trometamin, poželjno iz grupe koju čine L-arginin, dietanolamin, meglumin, trietanolamin i trometamin.
The rotating machine according to claim 15, wherein the machine comprises several pairs of mechanisms (1), placed in series and synchronised within each pair, the several pairs of mechanisms being placed in parallel and synchronised among themselves. 
Rotacijski stroj prema zahtjevu 9 naznačen time da se stroj sastoji od više parova mehanizama (1) s polugom (4), pri čemu su mehanizmi (1) poredani u seriju i sinkronizirani unutar svakog para, a parovi poredani paralelno i međusobno sinkronizirani.
The method of claim 45, wherein the cancer is selected from the group consisting of prostate cancer, lung cancer, colon cancer, baldder cancer, ovarian cancer, and Ewing's sarcoma. The method of claim 45, wherein the patient is administered a chemotherapeutic agent in combination with the antibody-drug conjugate compound, where the chemotherapeutic agent is selected from letrozole, cisplatin, carboplatin, taxol, paclitaxel, oxaliplatin, doxetaxel, 5-FU, leucovorin, lapatinib, and gemcitabine. 
farmaceutski prihvatljiv razrjeđivač, nosač ili farmaceutski prihvatljivo pomoćno sredstvo. 16. Farmaceutska formulacija prema zahtjevu 15, naznačena time, da se upotrebljava u postupku liječenja raka prostate, raka pluća ili raka crijeva, pri čemu taj postupak obuhvaća davanje pojedincu učinkovitu količinu farmaceutske formulacije, gdje se po želji pacijentu daje kemoterapeutsko sredstvo u kombinaciji sa spojem konjugata protutijela-lijeka, dok je kemoterapeutsko sredstvo odabrano od sljedećih: letrozol, cisplatin, karboplatin, 10
The isolated antibody of claim 1 wherein the amino acid sequence of said protein consists of the amino acid sequence according to SEQ ID NO: 2. 
Antitijelo iz bilo kojeg od patentnih zahtjeva 1-5 gdje se aminokiselinska sekvenca spomenutog proteina sastoji od aminokiselinske sekvence u skladu sa SEK ID BR: 2.
The container system according to claim 1, wherein the second of said at least two connecting arrangements comprises at least one of a film-shaped, brittle and unstable opening region, wherein the first of said at least two connecting arrangements is configured to open the second of said at least two connecting arrangements. 
Spojni sustav prema jednom od prethodnih patentnih zahtjeva, naznačen time, da drugi spojni raspored (3B, 3B') obuhvaća jedan, prvenstveno nalik na foliju, lomljiv i/ili nestabilan prostor za otvaranje (4B, 4B'), pri čemu je poželjno prvi spojni raspored (3A, 3A') oblikovan tako, da otvori drugi spojni raspored (3B, 3B').
a composition comprising a therapeutically effective amount of at least one first agent chosen from 2-acetylnaphtho[2,3-b]furan-4,9-dione and pharmaceutically acceptable solvates thereof, 
Kombinacija iz patentnog zahtjeva 1, pri čemu je prvi agens 2-acetilnafto[2,3-b]furan-4,9-dion, a drugi agens je gemcitabin, pri čemu je prvi agens formuliran u sastavu koji sadrži Gelucire&.
exhibits overexpression, translocation, amplification, or rearrangement of a myc family oncoprotein; results from aberrant regulation of BET proteins; 
je povezan s prekomjernom ekspresijom, translokacijom, amplifikacijom, ili rearanžmanom onkoproteina obitelji myc koji je osjetljiv na inhibiciju BET;
The process of clause 7, wherein the 1,1,1,3-tetrachloropropane and chlorine are introduced with a feed ratio of from about 0.9 to about 1.1 mole chlorine per mole tetrachloropropane. 
Postupak iz patentnog zahtjeva 7, pri čemu su 1,1,1,3-tetrakloropropan i klor uvedeni uz omjer dodavanja od 0.9 do 1.1 mola klora po molu tetrakloropropana.
is 2-aminophenyl, or a pharmaceutically acceptable salt thereof. 
R7 je 2-aminofenil, ili njegova sol.
The method of claim 23 wherein the additional therapeutic agents are selected from the group consisting of CFTR modulators and CFTR amplifiers. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 18, naznačen time što se dodatna terapijska sredstva bira iz skupine koju čine modulatori CFTR i amplifikatori CFTR, po mogućnosti modulatori CFTR.
After an appropriate planing of the surface of the boards, on one side, an adhesive/glue 20 was applied in the form of stripes with a device for the application of an adhesive of the company Lamello AG (device LK5PUR). 
Nakon odgovarajućeg ravnanja površine ploča, na jednoj strani je bilo naneseno adheziv/ljepilo 20 kompanije Lamello AG (tipa LK5SPUR) u obliku traka.
A typical substrate is a metal surface, optionally pretreated e.g. 
Tipična podloga je metalna površina, prema potrebi prethodno obrađena npr.
A coupling element as claimed in claim 1 characterised in that the third portion (14) has its other end bent at 90° to form a step (20) with a further portion (22) lying in a plane parallel to the plane in which the third portion (14) lies. 
Spojni element u skladu s patentnim zahtjevom 1, naznačen time što je trećem dijelu (14) drugi kraj svinut pod 90° kako bi činio pregib (20) prema daljnjem dijelu (22) koji leži u ravnini paralelnoj ravnini u kojoj leži treći dio (14).
The buffer(s) is usually present in the inner layer in an amount from about 0.1 to about 20 wt %, e.g. from about 0.1 to about 4 wt %, preferably from about 0.1 to about 3 wt %, and more preferably about 1 wt %, based on the dry weight of the third polymeric material. 
Formulacija lijeka s odloženim otpuštanjem sukladno u jednom od prethodnih patentnih zahtjeva, naznačeno time, da je pufer prisutan u unutarnjem sloju u količini od 0,1 wt % do 20 wt % na temelju suhe težine trećeg polimernog materijala.
In one embodiment, the pharmaceutical composition comprises at least one antigen binding protein and pharmaceutically acceptable carrier, diluents and/or adjuvants for the diagnosis, prevention or treatment of cancer, such as, for example, breast cancer, gastrointestinal cancer, pancreas cancer, prostate cancer, ovarian cancer, stomach cancer, endometrial cancer, salivary gland cancer, lung cancer, kidney cancer, colon cancer, colorectal cancer, thyroid cancer, bladder cancer, glioma, melanoma, other HB-EGF expressing or overexpressing cancers, and formation of tumor metastases. 
Farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 16, pri čemu je navedeni rak odabran iz grupe koju čine rak dojke, rak gastrointestinalnog trakta, rak gušterače, rak prostate, rak jajnika, rak želuca, rak endometrija, rak žlijezda slinovnica, rak pluća, rak bubrega, rak debelog crijeva, kolorektalni rak, rak štitne žlijezde, rak HR P20130903 T1 mjehura, gliom, melanom, karcinom, posebno epitelni iliskvamozni karcinom, druge vrste raka koje eksprimiraju ili pojačano eksprimiraju HB-EGF i stvaranje metastaza tumora.
Method according to any of the claims 1, wherein the aqueous solution comprising a dissolved salt of Micafungin and the aqueous solution in step b) of the present method comprises 2-30% v/v of a water miscible organic solvent. 
Postupak prema zahtjevu 1, naznačen time da vodena otopina sadrži otopljenu sol Micafungina u koraku a) i vodena otopina u koraku b) prema predmetnom postupku sadrži 2-30% v/v organskog otapala koje se miješa s vodom.
Polymer fiber obtainable by melt-spinning of a polymer and subsequent treatment of the fiber with ionizing radiation, wherein the polymer is a polypropylene homopolymer, a polypropylene copolymer or a mixture thereof, the polymer fiber has a length in the range of 0.1 to 40 mm, a diameter in the range of 5 to 170 µm and an MFI of more than 500 g/10 min, measured according to DIN EN ISO 1133 at 230°C/2,16 kg. 
Polimerno vlakno, koje se može dobiti predenjem polimera iz taline, uz naknadnu obradu ionizirajućim zračenjem, naznačeno time što je navedeno polimerno vlakno polipropilenski homopolimer, polipropilenski kopolimer ili njihova smjesa, gdje je duljina polimernog vlakna u rasponu do 0,1 do 400 mm, promjer je u rasponu od 5 do 170 lum, a MFI je veći od 500 g/10 min, što je izmjereno prema standardu DIN EN ISO 1133, na 230 *C/2,16 kg.
an LED disposed on one end of said housing; 
- < LED diodu postavljenu na jednom kraju navedenog kućišta:
wherein R1 is halo-substituted or unsubstituted benzyl and R2 is hydrogen or halogen; or wherein R1 and R2 are each hydrogen. 
pri čemu R1 je halo-supstituirani ili nesupstituirani benzil i R2 je vodik ili halogen; ili pri čemu R1 i R2 su svaki vodik.
The shaped article according to any one of claims 1 to 5, wherein the elastomeric material is a closed or an open cell foam, preferably a closed cell foam with a closed cell content of at least 70%. 
Oblikovani članak (100) prema bilo kojem od patentnih zahtjeva 1 do 5, pri čemu je elastomerni materijal zatvorena ili otvorena stanična pjena, poželjno zatvorena stanična pjena sa sadržajem zatvorene ćelije od najmanje 70%.
Use of a salt according to any of claims 1-8 in the preparation of a medicament for the treatment of schizophrenia or other psychotic disorders. 
Uporaba soli prema bilo kojem od zahijeva 1-8 u pripremi lijeka za liječenje shizofrenije ili drugih psihotičnih poremećaja.
The process according to claim 1, in which said partial hydrolysis is initiated with an amount of initial enzymatic cocktail in the range of from 1 mg to less than 10 mg per gram of cellulose in the lignocellulosic materials which have undergone a pre-treatment step. 
Postupak prema jednom od zahtjeva 1 do 8, naznačen time što navedeni korak hidrolize započinje s 1 do 60 mg enzimskog koktela po gramu celuloze u lignoceluloznom materijalu koji je podvrgnut koraku prethodne obrade.
A plant according to any one of the preceding claims, characterized in that the communicating duct (18) has no mechanical closure devices. 
Postrojenje u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time što komunikacijski vod (18) nema uređaje za mehaničko zatvaranje.
without formulation auxiliaries, amounts in general to 0.1 to 5000 g/ha, preferably 1 to 3000 g/ha, in particular 5 to 2500 g/ha, of active substance (a.s.), depending on the intended aim, the season, the target plants and growth stage. 
bez pomoćnih sredstava za formulaciju, iznosi generalno od 0.1 do 5000 g/ha, poželjno 1 do 3000 g/ha, posebno poželjno 5 do 2500 g/ha, aktivne supstance, u ovisnosti od namjeravanog cilja, sezone, ciljnih biljaka i stadija rasta.
Cortexolone-17a-propionate in crystalline form I according to claim 12 or 13 for use in treating pathologies affecting the urogenital system, the endocrine system, the skin and/or the cutaneous appendages. 
Korteksolon-17a-propionat u kristalnom obliku I u skladu s bilo kojim od patentnih zahtjeva 17 do 18, naznačen time što je namijenjen upotrebi u liječenju patoloških pojava koje pogađaju urogenitalni sustav, endokrini sustav, kožu i/ili kožne adnekse.
The pharmaceutical composition according to claim 18, wherein said chemotherapeutic agent is selected from the group consisting of a tyrosine kinase inhibitor, a phosphorylation cascade inhibitor, a post-translational modulator, a cell growth or division inhibitor, an antimitotic, a signal transduction inhibitor, and combinations thereof. 
Farmaceutski sastav prema zahtjevu 18, naznačen time, da navedeno kemoterapeutsko sredstvo je odabrano iz skupine koju čine inhibitor kinaze tirozina, inhibitor kaskadne fosforilacije, post-translacijski modulator, inhibitor staničnog rasta ili stanične diobe, antimitotik, inhibitor signalne transdukcije, te njihove kombinacije.
The method of claim 25, wherein the lyophilized formulation is stored for at least a year. 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što se formulaciju skladišti u trajanju od najmanje godine dana.
Aspect 13. Process according to anyone of aspects 1 to 3, and 6 to 11, wherein the shaping step (iv) is carried out in a mould with at least one rounded shape, preferably a mould which has multiple tandemly arranged rounded shapes. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time, da se korak oblikovanja (iv) provodi u kalupu s najmanje jednim zaobljenim oblikom, poželjno kalupom koji ima višestruko zaobljene oblike raspoređene u paru.
In still other embodiments, the active agent will be present in a concentration of about 5% to about 20% (w/w) or about 5% to about 15% (w/w) in the composition. 
HR P20191004 T1 d) ovlaživač je glicerin i prisutan je u koncentraciji od oko 5% do oko 20% (masa/masa); i e) tenzid je polietilenglikol-12-hidroksistearat i prisutan je u koncentraciji od oko 1% do oko 5% (masa/masa).